0001302605-14-000001.txt : 20140415
0001302605-14-000001.hdr.sgml : 20140415
20140415215917
ACCESSION NUMBER: 0001302605-14-000001
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140414
FILED AS OF DATE: 20140415
DATE AS OF CHANGE: 20140415
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001080709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 232908305
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-453-7200
MAIL ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nova Tina Susan
CENTRAL INDEX KEY: 0001302605
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31161
FILM NUMBER: 14766456
MAIL ADDRESS:
STREET 1: C/O ARENA PHARMACEUTICALS, INC.
STREET 2: 6166 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER NAME:
FORMER CONFORMED NAME: Nova Bennett Tina
DATE OF NAME CHANGE: 20080226
FORMER NAME:
FORMER CONFORMED NAME: Nova Tina Susan
DATE OF NAME CHANGE: 20040908
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2014-04-14
0001080709
ARENA PHARMACEUTICALS INC
ARNA
0001302605
Nova Tina Susan
C/O ARENA PHARMACEUTICALS, INC.
6154 NANCY RIDGE DRIVE
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2014-04-14
4
M
0
25000
4.11
A
43728
D
Common Stock
2014-04-14
4
M
0
10000
6.16
A
53728
D
Common Stock
2014-04-14
4
S
0
35000
6.2218
D
18728
D
Stock Option (right to buy)
4.11
2014-04-14
4
M
0
25000
0
D
2004-09-14
2014-09-14
Common Stock
25000
0
D
Stock Option (right to buy)
6.16
2014-04-14
4
M
0
10000
0
D
2005-01-17
2015-01-17
Common Stock
10000
0
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.01 and $6.33 per share, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The options were exercisable upon grant, but vested in two equal annual installments beginning on September 14, 2005.
The options were exercisable upon grant, but vested monthly over one year.
Adam S. Chinnock, as Attorney-in-Fact
2014-04-15